This stock is obviously well off the radar screen here in Australia and maybe after the Ventracor debacle investors are reluctant to revisit similar stocks. However l believe they are going to kick serious arse and the latest quarterly report and webcast are now indicating where they are heading. Revenues are growing very nicely outside of the USA, the DT trials are well underway and FDA approval for the US market is now getting closer.
pc_75au you mentioned clotting issues, with heartwares product it's not an issue or at the most a minor one which is evidenced by the success they are enjoying.
l just hope some vulturistic multinational doesn't come along and spoil our long term super investment with a takeover.
HIN Price at posting:
$1.59 Sentiment: Buy Disclosure: Held